Iodide

Iodide

SCHEMBL4041064

C[N+]1(C)CCC(=O)CC1.[I-]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 1/20 0.33
CHRM3 known ✓ P20309 1/20 0.33
TRIM24 O15164 2/20 0.37
TRIM33 Q9UPN9 2/20 0.37
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP2D6 P10635 1/20 0.33
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
HTR2B P41595 1/20 0.33
CHRNA4 P43681 1/20 0.33
HTR3A P46098 1/20 0.33
KCNH2 Q12809 1/20 0.33
CHRNA7 P36544 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
APOBEC3A P31941 1/20 0.30
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4441326 0.97
Bromide SCHEMBL3225071 0.94 TRIM24 (0.37) TRIM24TRIM33ALDH1A1LMNACHRM2
Hydrochloric Acid SCHEMBL3732793 0.94 TRIM24 (0.37) TRIM24TRIM33ALDH1A1LMNACHRM2
SCHEMBL8352753 0.84 TRIM24 (0.30) TRIM24TRIM33
Trifluoromethanesulfonic Acid SCHEMBL8388996 0.75 ACHE (0.33)
SCHEMBL4836270 0.73
Iodide SCHEMBL11340215 0.71
SCHEMBL739073 0.69 TRIM24 (0.32) TRIM24TRIM33ALDH1A1
Bromide SCHEMBL4087944 0.67 TRIM24 (0.30) TRIM24TRIM33
Iodide SCHEMBL4706138 0.67 MEN1 (0.33) KDM4EMEN1POLBAPOBEC3APMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070243221-A1 ANTI-WRINKLE COMPOSITION L'OREAL (FR) 2007-10-18 US claimed
EP-4603480-A1 INDOLE PHTHALOCYANINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN TUMOR DIAGNOSIS IMAGING Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-08-20 EP disclosed
US-20250059159-A1 PLPRO INHIBITORS HUAHAI US INC. 2025-02-20 US disclosed
EP-4448515-A1 PLPRO INHIBITORS Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) 2024-10-23 EP disclosed
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-10-03 US disclosed
CN-113473987-B Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same 细胞基因公司 2024-09-03 CN disclosed
US-20240246070-A1 PIPERIDINIUM-CONTAINING ANION EXCHANGE POLYMERS VERSOGEN, INC. 2024-07-25 US disclosed
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-21 US disclosed
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 CN disclosed
EP-4323352-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-02-21 EP disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-1173472-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-23 EP disclosed
WO-2000064927-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 WO disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed
US-5756508-A Muscarine antagonists MERCK & CO., INC. (US) 1998-05-26 US disclosed
US-5691323-A BENZIMIDAZOL-2-ONES MERCK & CO., INC. (US) 1997-11-25 US disclosed
US-5668153-A Piperidine derivatives and their use as therapeutic agents MERCK SHARP & DOHME, LTD. (GB) 1997-09-16 US disclosed
WO-1997016192-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1997-05-09 WO disclosed
WO-1996013262-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1996-05-09 WO disclosed
WO-1993014084-A2 PIPERIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB CHRM1 16/4885CHRM3 146/4885TRIM24 841/4885
US-20070243221-A1 ANTI-WRINKLE COMPOSITION NR2C2, FFAR3, NR1I2 CHRM1 32/4885CHRM3 61/4885TRIM24 2804/4885
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 CHRM1 4742/4885CHRM3 4680/4885TRIM24 917/4885
US-20250059159-A1 PLPRO INHIBITORS SARS1, PLP2, PLPBP CHRM1 4689/4885CHRM3 4220/4885TRIM24 444/4885
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 CHRM1 4742/4885CHRM3 4680/4885TRIM24 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.